ABSTRACT

FDA states that Blood Diseases are the conditions impair the functional ability of blood by affecting one or more blood components & the Blood Disorders are uncertainty that your platelets, red or white blood cells, or blood clotting proteins aren't working correctly, you might have a blood disorder. Centre for Drug Evaluation and Research's (CDER) Division of Non-Malignant Haematology. "This action demonstrates the FDA's dedication to assisting patients with rare diseases in accessing new treatments." The regulatory pathway guarantees a thorough evaluation of treatments safety and efficacy prior to patient administration. Gathering information from clinical trials about the treatment's effectiveness and safety is a crucial step in this process. Advisory groups and government oversight organizations offer a further degree of examination to guarantee that the benefits of the treatment. In terms of safety, the FDA emphasizes a thorough risk-benefit analysis, with a focus on minimizing potential risks associated with the treatment. Detailed pharmacovigilance plans and long-term follow-up studies are often required to monitor post-marketing safety. FDA's dedication to promoting innovation, enhancing patient safety, and developing cutting-edge therapies for these difficult diseases to provide patients with rare blood diseases life-changing treatments, developers and stakeholders must carefully meet these requirements. Keywords: Blood Disease, Blood Disorders, CDER, FDA, Approval Process
Publication date: 01/12/2025

https://ijbpas.com/pdf/2025/December/MS_IJBPAS_2025_9685.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2025/14.12.9685